COMBINATION CHEMOTHERAPY WITH ORAL ETOPOSIDE PLUS INTRAVENOUS CYCLOPHOSPHAMIDE IN LIVER METASTASES OF BREAST-CANCER

被引:7
作者
ESTAPE, J
DANIELS, M
VINOLAS, N
SANTABARBARA, P
GRAU, JJ
GARDELLA, S
机构
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1990年 / 13卷 / 02期
关键词
D O I
10.1097/00000421-199004000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sixteen patients with hepatic metastases of histologically documented breast cancer were treated with etoposide (VP 16-213) and cyclophosphamide. Previously, 6 had shown relapse in the liver after adjuvant chemotherapy, 2 had failed to respond to another chemotherapy combination, and 8 had never undergone chemotherapy. Fifty percent responded to treatment, including 1 complete remission and 7 partial responses. Median survival was 16 months and median duration of response was 13 months. All patients showed alopecia and moderate leukopenia: 13 experienced moderate gastrointestinal toxicity; there was 1 mild case of anemia and 1 case of moderate hemorrhagic cystitis. This study suggests that the combination of VP 16-213 and cyclophosphamide is a well-tolerated and effective treatment in advanced breast cancer patients with liver metastases.
引用
收藏
页码:98 / 100
页数:3
相关论文
共 15 条
  • [1] DOMBERNOWSKY P, 1973, ACTA PATH MICRO IM A, VA 81, P715
  • [2] ESTAPE J, 1983, CANCER CHEMOTH PHARM, V10, P154
  • [3] ESTAPE J, 1979, CANCER, V43, P72, DOI 10.1002/1097-0142(197901)43:1<72::AID-CNCR2820430110>3.0.CO
  • [4] 2-1
  • [5] ESTAPE J, 1983, CANCER, V51, P385, DOI 10.1002/1097-0142(19830201)51:3<385::AID-CNCR2820510305>3.0.CO
  • [6] 2-K
  • [7] ESTAPE J, 1982, NEW APPROACHES CANCE, P15
  • [8] PROGNOSTIC FACTORS IN INITIAL RESPONSE TO THERAPY BY PATIENTS WITH ADVANCED BREAST-CANCER
    GEORGE, SL
    HOOGSTRATEN, B
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1978, 60 (04) : 731 - 736
  • [9] HELLMAN S, 1982, CANCER PRINCIPLES PR, P914
  • [10] ISSELL BF, 1982, CANCER CHEMOTH PHARM, V7, P73